Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashraf Nashed

Cardiovascular Disease Thousand Oaks, CA Medical Doctor

NPI 1144290081 CMS profile 52027

415 Rolling Oaks Dr, Ste 250, Thousand Oaks, CA 91361

Open in the dashboard

General payments

$22,687

562 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashraf Nashed of Thousand Oaks, CA is reported in the CMS Open Payments database as having received $22,687 across 562 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,232 46
2024 General $4,144 82
2023 General $1,861 63
2022 General $5,485 100
2021 General $2,310 85
2020 General $2,288 89
2019 General $4,366 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashraf Nashed
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ashraf Nashed were reported at $2,232. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ashraf Nashed Cardiovascular Disease median Middle half National median
2019 $4,366 $450 $127–$1,392 $163
2020 $2,288 $242 $77–$751 $114
2021 $2,310 $335 $101–$1,037 $132
2022 $5,485 $395 $121–$1,211 $149
2023 $1,861 $443 $136–$1,283 $160
2024 $4,144 $450 $136–$1,323 $164
2025 $2,232 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Philips Electronics North America Corporation $4,201 32 payments
  2. Abbott Laboratories $2,985 38 payments
  3. Biotronik Inc. $2,000 10 payments
  4. AstraZeneca Pharmaceuticals LP $1,975 60 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,244 50 payments
  6. Novartis Pharmaceuticals Corporation $1,214 85 payments
  7. Amarin Pharma Inc. $927 36 payments
  8. CVRx, Inc. $863 9 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $859 29 payments
  10. Merck Sharp & Dohme Corporation $739 26 payments
  11. Other $5,680 187 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,683 523 payments
  2. Travel and Lodging $4,035 22 payments
  3. Education $1,969 17 payments
Products named General payments · program years 2019–2025
  1. (1399) MRI Equip Undiv $1,726 8 payments
  2. FARXIGA $1,018 30 payments
  3. (6554) Peripheral Vascular Undivided $985 12 payments
  4. JARDIANCE $898 34 payments
  5. Barostim Neo System $863 9 payments
  6. VERQUVO $820 23 payments
  7. BRILINTA $777 20 payments
  8. ENTRESTO $719 55 payments
  9. Vascepa $716 29 payments
  10. Kerendia $527 18 payments
  11. Other $14,054 420 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 200 drugs

Part D claims

20,092

Median for Cardiology: 2,533

Drug cost

$2,845,781

Median for Cardiology: $485,213

Branded share of claims

26.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 376 $359,652
Mounjaro Tirzepatide Brand 271 $289,493
Jardiance Empagliflozin Brand 415 $267,093
Eliquis Apixaban Brand 416 $233,580
Diclofenac Sodium Generic 119 $204,869
Xarelto Rivaroxaban Brand 266 $156,395
Linzess Linaclotide Brand 196 $105,166
Entresto Sacubitril/Valsartan Brand 114 $94,141
Januvia Sitagliptin Phosphate Brand 162 $92,379
Forteo Teriparatide Brand 20 $88,389

The 10 drugs with the highest cost, of 200 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$814,580

Of which drugs: $10,691

Medicare patients

721

Average age 76

Services billed

11,389

403 women, 318 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Diabetes 57%
Ischemic heart disease 57%
Heart failure 43%
Atrial fibrillation 39%
Depression 39%
Chronic kidney disease 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 32 132 $668
Infusion, normal saline solution, 250 cc J7050 Office 32 33 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $210
$210 92 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $205
$205 19 —
VERQUVO
  • Merck Sharp & Dohme Corporation $200
$200 18 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $165
$165 415 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $157
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

562 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record